The US FDA approved Sage Therapeutics Inc.'s Zulresso (brexanolone) on March 19 as the first agency-endorsed treatment for postpartum depression (PPD). It's also Sage's first approved product, helping the company establish a commercial organization as it completes Phase III development for the more broadly applicable postpartum and major depression candidate SAGE-217.
Zulresso's 60-hour I.V. infusion and requirement for continuous inpatient monitoring during administration may limit its use to the most at-risk...
